New Array-based Prostate Cancer Panel Is Sensitive, Specific; Future PSA Alternative? | GenomeWeb

Researchers at the University of Michigan along with a crew of Boston scientists have discovered a 22-protein panel of biomarkers that was able in preliminary studies to identify prostate cancer with 82 percent sensitivity and 88 percent specificity.

The news is noteworthy because it could lead to the development of an alternative diagnostic to standard prostate specific antigen tests, which return false positives around 80 percent of the time and therefore trigger unnecessary prostate biopsies.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.